Claudio Dansky Ullmann, MD

Doug Doerfler
President and Chief Executive Officer

Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Previously, Mr. Doerfler was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company.

He also held various executive positions with Life Technologies, Inc. (now Thermo Fisher) that included leading its global businesses, mergers and acquisitions and its initial public offering (“IPO”). Mr. Doerfler plays an active role as a life sciences industry advocate, serving as Chair Emeritus of the Maryland Tech Council and on the executive committee of the Biotechnology Innovation Organization.

Mr. Doerfler received his BS in finance from the University of Baltimore School of Business, and holds a certificate in Industrial Relations.

Claudio Dansky Ullmann, MD

Amanda L. Murphy
Chief Financial Officer

Ms. Murphy joined MaxCyte as Chief Financial Officer in 2020. Before joining MaxCyte, Ms. Murphy, a senior equity analyst focused on the biotechnology industry, served as Managing Director of BTIG, LLC. She has specialized in gene therapy, gene editing and cell therapy for both burgeoning private and established public healthcare companies. Prior to BTIG, she was a Partner and Healthcare Analyst at William Blair & Company, focused on diagnostic services and life sciences. Previously, Ms. Murphy was a Business Analyst at Caremark and a Senior Consultant within the Strategy Consulting division at PricewaterhouseCoopers. She received a BS in biology from Boston College’s honors program, and an MBA in finance, accounting and economics from the Kellogg Graduate School of Management at Northwestern University.

Claudio Dansky Ullmann, MD

Ron Holtz
Senior Vice President and Chief Accounting Officer

Mr. Holtz serves as MaxCyte’s Senior Vice President and Chief Accounting Officer (CAO), having joined the Company in 2005. Previously, he has been CFO of both public and private companies and has raised more than $150 million in debt and equity capital. He also had previous experience with Ernst & Young LLP’s Financial Advisory Services Group. He earned an MBA in finance from the University of Maryland, a BS in mathematics from the University of Wisconsin and is a Certified Public Accountant.

Claudio Dansky Ullmann, MD

Brad Calvin
Chief Commercial Officer

Mr. Calvin is a 25-year veteran within the diagnostics, devices, drug discovery and life sciences industries. In his role as MaxCyte’s Chief Commercial Officer, he is responsible for leading the Company’s sales, marketing and business development functions to define product strategy, deliver new products and drive growth of its drug discovery and cell therapy businesses. Mr. Calvin was most recently Co-founder and President of AsedaSciences, a company with an integrated technology platform to predict in vivo toxicity risk in early-stage drug discovery. Previously, he has held various global and regional leadership positions at companies ranging from large corporations to start-ups, such as Accuvein, Beckman Coulter, Qiagen, Digene, AGENIX, and Abbott Laboratories. He has a Bachelor’s degree in Applied Science from Curtin Institute of Technology in Perth, Western Australia.

Claudio Dansky Ullmann, MD

Thomas M. Ross
Executive Vice President, Global Sales

Mr. Ross serves as MaxCyte’s Executive Vice President of Global Sales, having joined the Company in 2014. Mr. Ross has extensive experience in all elements of commercial operations and has more than 25 years of successful sales and marketing leadership in the Life Science and Clinical Diagnostics markets. Most recently, Mr. Ross was Senior Vice President of Commercial Operations at OpGen®. Mr. Ross also served as Chief Commercial Officer at Predictive BioScience and Vice President of North America Medical Diagnostics Sales at Qiagen/Digene Corporation. Prior to working at Digene Corporation, he held several senior leadership roles in Manufacturing Operations at Life Technologies, Inc. and Cambrex. Mr. Ross has a Bachelor’s of Business Administration from The Citadel.

Claudio Dansky Ullmann, MD

Maher Masoud
Executive Vice President and General Counsel

Mr. Masoud brings to MaxCyte 21 years of experience as an attorney and general counsel in the biotech industry. He has served as Assistant General Counsel and Corporate Secretary for Wellstat Management Company; co-founding partner of Rossi/Masoud LLC, a specialized law firm for the biotech, pharmaceutical and IT sectors; and Corporate Attorney at Human Genome Sciences, Inc. Mr. Masoud managed the legal team on the launch of two FDA-approved drugs while at Wellstat. At Human Genome Sciences, he assisted with FDA compliance for the product launch of Benlysta®, negotiated and executed more than 1,000 clinical trial agreements, negotiated licensing deals valued at over $300 million, and assisted the company with raising financing through bond and secondary stock offerings in excess of $800 million. A member of the Maryland State Bar, Mr. Masoud holds a JD from Michigan State University College of Law, and a BS in Cell & Molecular Biology Genetics from the University of Maryland.

Claudio Dansky Ullmann, MD

James Brady, PhD
Vice President, Technical Applications and Customer Support

Dr. Brady is Vice President of Technical Applications and Customer Support at MaxCyte, Inc. Prior to joining MaxCyte in 2004, Dr. Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments for ocular disorders. Previously, he worked at MetaMorphix, Inc. as a Group Leader in the Company’s Transgenic Livestock program, and was a postdoctoral fellow at the National Eye Institute of the National Institutes of Health. Dr. Brady received a Bachelor of Science degree in biology from the College of William and Mary, a Ph.D. in genetics from Indiana University and an MBA from Johns Hopkins University.

Claudio Dansky Ullmann, MD

Sarah Haecker Meeks, PhD
Vice President, Business Development

Before joining MaxCyte, Dr. Meeks served as Vice President of Business Development at Synpromics (now part of AskBio) where she established a leading market position for the company, including partnerships with leading gene therapy companies, and led broad technology education and adoption initiatives. Prior to her work at Synpromics, she was the Chief Scientific Officer at Adjuvant Partners. She received a PhD in biochemistry, molecular biology and biophysics, with a minor in bioethics, from the University of Minnesota and completed postdoctoral work in the University of Pennsylvania Gene Therapy Program and Center for Technology Transfer with continued education in the Wharton MBA Program.

Claudio Dansky Ullmann, MD

Steve Nardi
Vice President, Manufacturing and Engineering Operations

Before joining MaxCyte, Mr. Nardi served as Vice President of Worldwide Manufacturing at Iradimed Corporation where he introduced lean manufacturing principles, and improved transparency, cost control and accountability. Prior to his work at Iradimed, Mr. Nardi was the Senior Manager of Manufacturing and Engineering at Haemonetics Corporation. He received both a BS in Science, Engineering and Technology and an MS in Technology Commercialization at Northeastern University.

Claudio Dansky Ullmann, MD

Kathryn Wekselman
Vice President, Regulatory

Dr. Wekselman is a senior drug development expert with extensive experience in drug development, clinical protocol development and execution, and interactions with regulatory authorities, including leading or developing marketing application submissions to the U.S. Food and Drug Administration (FDA), the European Medicines Agency and Health Canada for drugs, biologics and medical devices. She has 10 years of clinical research organization experience as a consultant to pharmaceutical, biotechnology, and device companies, and nine years at Procter & Gamble Pharmaceuticals, where she held positions in medical writing, medical monitoring, and project leadership. Dr. Wekselman earned her BSN (summa cum laude) and PhD in nursing from the University of Cincinnati. She had 10 years of clinical and academic experience in nursing before joining the industry to work in drug development. She has authored more than 25 journal articles or book chapters and has presented more than 30 posters, conference sessions, guest lectures and professional education seminars.

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Sign Up